Loading the records…
Loading the records…
Veterans Affairs · 262-NETWORK CONTRACT OFFICE 22 (36C262)
Veterans Affairs awarded "Emergency Pluvicto and Lutathera" to Novartis Pharmaceuticals Corporation for $769K. In the last 2 years, similar work went to 10 or more companies, usually for about $1.6M per award.
Put together from the facts on this page; the details and sources are below.
No listed company matched (Materiality N/A)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Every notice posted under solicitation 6912710440008 in this department, oldest first.
Standard steps for the notice type; not advice about this buyer.
27 award notices on SAM.gov in the last 24 months. Matched by: Same office (262-NETWORK CONTRACT OFFICE 22 (36C262)), same product/service code (PSC) 6505 and NAICS 325412.
Single-winner award sizes (27): middle half $501K to $3.4M, median $1.6M; range $53K to $37.3M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| EXELAN PHARMACEUTICALS INC | 9 | $42.2M | Jan 28, 2026 |
| RLS (USA) INC. | 4 | $9.6M | Mar 5, 2026 |
| CARDINAL HEALTH 414, LLC |
| 4 |
| $929K |
| Oct 1, 2026 |
| Novartis Pharmaceuticals Corporation | 2 | $8.9M | Jan 8, 2026 |
| BOSTON SCIENTIFIC CORP · $BSX · $21.0B | 2 | $1.4M | Dec 23, 2025 |
| PROGENICS PHARMACEUTICALS INC | 2 | $1.2M | Aug 21, 2025 |
| SIRTEX MEDICAL INC | 1 | $37.3M | Nov 12, 2025 |
| ADVANCED ACCELERATOR APPLICATIONS USA INC | 1 | $993K | Dec 16, 2024 |
| TELIX PHARMACEUTICALS US INC | 1 | $496K | Apr 22, 2026 |
| Bristol-Myers Squibb Company | 1 | $364K | Jun 30, 2026 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
One award's total value against one year of revenue; many awards are paid over several years.
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.